Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591487731> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2591487731 endingPage "563" @default.
- W2591487731 startingPage "563" @default.
- W2591487731 abstract "563 Background: Recent pharmacogenetic studies have revealed a significant association between uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) polymorphisms *28 and *6 and toxicities such as severe diarrhea and neutropenia under treatment with irinotecan. Moreover, the latter of these two polymorphisms is specifically detected in East Asian populations. We performed a prospective study to determine the optimal dose of this drug depending on which polymorphism is present in order to maximize the effectiveness of therapy while avoiding side effects. Methods: 59 patients from 11 institutions were enrolled in this study. Patients were assigned to one of the following three groups: wild type (*1/*1), heterozygous (*28/*1, *6/*1), or homozygous (*28/*28, *6/*6*, *28/*6*). The double heterozygous state (*28/*6) was included within the homozygous group. Second-line FOLFIRI was administered, with the dose of irinotecan at 150 mg/m2, in the wild type and heterozygous groups and at 100 mg/m2 in the homozygous group. The incidences of severe toxicities according to UGT1A1 gene type, response rate, and progression-free survival were investigated. Results: 26 (44.1%) were assigned to the wild type group, 28 (47.4%) to the heterozygous group, and 5 (8.5%) to the homozygous group. Grade 3 or higher severe toxicities were observed in 8 patients (30.8%) in the wild type group, 5 (17.9%) in the heterozygous group, and 1 (20.0%) in the homozygous group. No significant difference was observed among the three groups. The most frequently observed severe toxicities were neutropenia, nausea, vomiting, and diarrhea. The overall response rate (complete response + partial response) was 2 patients (7.7%) in the wild type group, 2 (7.1%) in the heterozygous group, and none (0.0%) in the homozygous group. Conclusions: In terms of tolerability and safety, the present results suggest that irinotecan should be administered at a dose of 150mg/m2 in heterozygous patients and 100 mg/m2 in homozygous patients receiving second-line FOLFIRI." @default.
- W2591487731 created "2017-03-03" @default.
- W2591487731 creator A5003529696 @default.
- W2591487731 creator A5009305808 @default.
- W2591487731 creator A5013703823 @default.
- W2591487731 creator A5019243331 @default.
- W2591487731 creator A5030397339 @default.
- W2591487731 creator A5041612127 @default.
- W2591487731 creator A5042621744 @default.
- W2591487731 creator A5053064222 @default.
- W2591487731 creator A5062939408 @default.
- W2591487731 creator A5066565101 @default.
- W2591487731 creator A5068761186 @default.
- W2591487731 creator A5087493207 @default.
- W2591487731 creator A5090129019 @default.
- W2591487731 creator A5090212259 @default.
- W2591487731 date "2014-01-20" @default.
- W2591487731 modified "2023-10-18" @default.
- W2591487731 title "A multicenter exploratory study of irinotecan-based chemotherapy on UGT1A1 polymorphisms for patients with colorectal cancer." @default.
- W2591487731 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.563" @default.
- W2591487731 hasPublicationYear "2014" @default.
- W2591487731 type Work @default.
- W2591487731 sameAs 2591487731 @default.
- W2591487731 citedByCount "0" @default.
- W2591487731 crossrefType "journal-article" @default.
- W2591487731 hasAuthorship W2591487731A5003529696 @default.
- W2591487731 hasAuthorship W2591487731A5009305808 @default.
- W2591487731 hasAuthorship W2591487731A5013703823 @default.
- W2591487731 hasAuthorship W2591487731A5019243331 @default.
- W2591487731 hasAuthorship W2591487731A5030397339 @default.
- W2591487731 hasAuthorship W2591487731A5041612127 @default.
- W2591487731 hasAuthorship W2591487731A5042621744 @default.
- W2591487731 hasAuthorship W2591487731A5053064222 @default.
- W2591487731 hasAuthorship W2591487731A5062939408 @default.
- W2591487731 hasAuthorship W2591487731A5066565101 @default.
- W2591487731 hasAuthorship W2591487731A5068761186 @default.
- W2591487731 hasAuthorship W2591487731A5087493207 @default.
- W2591487731 hasAuthorship W2591487731A5090129019 @default.
- W2591487731 hasAuthorship W2591487731A5090212259 @default.
- W2591487731 hasConcept C104317684 @default.
- W2591487731 hasConcept C121608353 @default.
- W2591487731 hasConcept C126322002 @default.
- W2591487731 hasConcept C135763542 @default.
- W2591487731 hasConcept C2776694085 @default.
- W2591487731 hasConcept C2776705615 @default.
- W2591487731 hasConcept C2777063308 @default.
- W2591487731 hasConcept C2777573665 @default.
- W2591487731 hasConcept C2779802037 @default.
- W2591487731 hasConcept C2780259306 @default.
- W2591487731 hasConcept C2780580376 @default.
- W2591487731 hasConcept C2780852908 @default.
- W2591487731 hasConcept C526805850 @default.
- W2591487731 hasConcept C55493867 @default.
- W2591487731 hasConcept C71924100 @default.
- W2591487731 hasConcept C86803240 @default.
- W2591487731 hasConcept C90924648 @default.
- W2591487731 hasConceptScore W2591487731C104317684 @default.
- W2591487731 hasConceptScore W2591487731C121608353 @default.
- W2591487731 hasConceptScore W2591487731C126322002 @default.
- W2591487731 hasConceptScore W2591487731C135763542 @default.
- W2591487731 hasConceptScore W2591487731C2776694085 @default.
- W2591487731 hasConceptScore W2591487731C2776705615 @default.
- W2591487731 hasConceptScore W2591487731C2777063308 @default.
- W2591487731 hasConceptScore W2591487731C2777573665 @default.
- W2591487731 hasConceptScore W2591487731C2779802037 @default.
- W2591487731 hasConceptScore W2591487731C2780259306 @default.
- W2591487731 hasConceptScore W2591487731C2780580376 @default.
- W2591487731 hasConceptScore W2591487731C2780852908 @default.
- W2591487731 hasConceptScore W2591487731C526805850 @default.
- W2591487731 hasConceptScore W2591487731C55493867 @default.
- W2591487731 hasConceptScore W2591487731C71924100 @default.
- W2591487731 hasConceptScore W2591487731C86803240 @default.
- W2591487731 hasConceptScore W2591487731C90924648 @default.
- W2591487731 hasIssue "3_suppl" @default.
- W2591487731 hasLocation W25914877311 @default.
- W2591487731 hasOpenAccess W2591487731 @default.
- W2591487731 hasPrimaryLocation W25914877311 @default.
- W2591487731 hasRelatedWork W1976646314 @default.
- W2591487731 hasRelatedWork W2030949051 @default.
- W2591487731 hasRelatedWork W2136955408 @default.
- W2591487731 hasRelatedWork W2320562621 @default.
- W2591487731 hasRelatedWork W2356972755 @default.
- W2591487731 hasRelatedWork W2386923354 @default.
- W2591487731 hasRelatedWork W2389892302 @default.
- W2591487731 hasRelatedWork W2897258609 @default.
- W2591487731 hasRelatedWork W3031975498 @default.
- W2591487731 hasRelatedWork W3142684436 @default.
- W2591487731 hasVolume "32" @default.
- W2591487731 isParatext "false" @default.
- W2591487731 isRetracted "false" @default.
- W2591487731 magId "2591487731" @default.
- W2591487731 workType "article" @default.